InnoVate AMR

Funding Bodies

IDRC

DHSC

Funds research in developing countries to create lasting change on a large scale

Generate local solutions, bringing choice and change to those who need it most in the developing world

Helping people to live more independent, healthier lives for longer

GAMRIF was established to support early-stage, innovative research and development, specifically targeting neglected and underinvested areas in the field of antimicrobial resistance (AMR).

Ultimate Outcome

Reduce the threat of antibiotic resistance to human health by minimising the misuse of antibiotics and the development and spread of antibiotics resistance in developing countries, through the development and uptake of innovative veterinary products.

Only consider vetinary solutrions that address

Infectious diseases of importance to low and middle income countries;

Reduction of use and/or misuse of antibiotics;

Antibiotic resistance (research projects can target any pathogen as long as a relevant link can be made to minimising the development and spread of antibiotic resistance and/or use/misuse of antibiotics).

Not considered

Do not consider antibiotic resistance

Do not consider swine, poultry or aquaculture (fish or shellfish)

Are focused on new antibiotic drug discovery

Are focused on improving animal husbandry and farm management

Are to develop diagnostic devices

Are focused on the development of surveillance platforms

Are to pilot test new biomarkers or combinations of biomarkers

Are to develop alternatives solutions to antibiotics not relevant to low and middle income countries

Are to carry out field trials only

Are designed for fundamental research, corresponding to TRL 1 and 2 (See Annex 2)

Are related only to registration or commercialization issues.

Essential

Develop innovative veterinary solutions, focusing on product development, to reduce the therapeutic (prevention and control) and non-therapeutic (growth promotion) use of antibiotics, while still protecting animal health and welfare.

Strong involvement of researchers, manufacturers and other organizations, as well as early involvement of regulatory authorities, in developing countries is critical when working towards accelerating the registration of veterinary products.

Gender equity: Proposals need to demonstrate how the project will involve women from all participating organisations comprising the research team and throughout the research process.


Commercialisation and Adoption Plan of the innovation should also demonstrate how women will be involved; including a strategy that explains how gender implication will be considered."

Environment: Proposals need to demonstrate that they have considered the potential environmental impacts of their activities, detailing potential benefits and describing how any potential harmful effects will be mitigated.

Understand and address the local contexts and realities which drive antibiotic-usage patterns on farms in developing countries, to ensure relevant innovations that are appropriate for the ultimate uptake and use by farmers, veterinarians and paraveterinarians in developing countries.

These solutions must target the prevention and control of infectious diseases of importance in low and middle income countries and the reduction of the use of antibiotics as growth promoters.

These product-oriented solutions include:

Development of vaccines, vaccine administration/delivery methods; or

Development of alternatives to antibiotics, including but not limited to pro- and pre-biotics, immunomodulators and bacteriophages."

Highest Priority

click to edit

 Present a compelling justification for the proposed innovative veterinary solution, are scientifically sound and clearly describe how this approach will curb antibiotic use and the development of antibiotic resistance in the livestock and aquaculture sectors in low and middle income countries

 Demonstrate clear plans for sustainability of the proposed solution

 Support innovations at the technology readiness level (TRL) 3 to 6 (see Annex 2 for further information), that is early-stage product development, excluding fundamental research

 Demonstrate strong capacity to generate timely results based on specific milestones and within the allocated budget

 Include and describe a future ‘Commercialization and Adoption plan’ for the veterinary solutions to be developed and ready for use in developing countries

 Include and describe effective partnerships with organizations in low and middle income countries (refer to Frequently Asked Questions)

 Show an awareness of medicines regulation and/or the intent to engage with a Government Regulatory Body for veterinary medicines in low and middle income countries.